News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
David Planchard: BRAF Duplication as Resistance in BRAFV600E Lung Adenocarcinoma
David Planchard/oncostream.com
Apr 17, 2025, 06:30

David Planchard: BRAF Duplication as Resistance in BRAFV600E Lung Adenocarcinoma

David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group at Gustave Roussy, shared a post on LinkedIn:

“BRAF Kinase Domain Duplication as a Potential On-Target Resistance Mechanism After Dabrafenib-Trametinib Therapy in a Patient With BRAFV600E-Mutated Lung Adenocarcinoma | JCO Precision Oncology.”

cancer David Planchard JCO Precision Oncology OncoDaily Oncology
Special Coverage
Blog
Apr 22, 2025, 13:59
The systemic therapy options available for mCRPC - National Comprehensive Cancer Network
Science
Apr 22, 2025, 13:49
Joshua Brody: How to measure T-cell BYSTANDER tumor killing to prevent antigen escape after cancer immunotherapy
Blog
Apr 22, 2025, 13:34
Sampad Roy: A potential paradigm shift in breast cancer treatment
Blog
Apr 22, 2025, 13:19
IASLC Board of Directors Elections 2025: Spotlight on Undesignated Seat Candidates
Oncolibrary
Apr 22, 2025, 13:02
Trodelvy and Keytruda Achieve Breakthrough Results, Ushering in a New Era for ADCs in Breast Cancer
Radiotherapy
Apr 22, 2025, 12:05
Success Rate and Survival After Stereotactic Radiotherapy
OncoDaily Pulse
Apr 22, 2025, 11:13
New section on OncoDaily - A space that brings all career opportunities into one place
Oncolibrary
Apr 22, 2025, 11:10
DESTINY-Breast09 trial: Enhertu + Pertuzumab Improves PFS in First-Line HER2+ Metastatic Breast Cancer
Blog
Apr 22, 2025, 11:06
How immune cell baselines may predict CD22 therapy outcomes in Pediatric Cancer - NCI Center for Cancer Research
Blog
Apr 22, 2025, 10:57
Register for MASCC25 at the early bird rate - The Multinational Association of Supportive Care in Cancer
Blog
Apr 22, 2025, 10:51
Amol Akhade: Sacituzumab govitecan plus pembrolizumab shows PFS benefit in metastatic TNBC
Blog
Apr 22, 2025, 10:44
Jeff Hunnicutt: Highlands Oncology Group announces a partnership with Agamon Health